Dyadic International, Inc. (DYAI)
| Market Cap | 130.61M |
| Revenue (ttm) | 1.60M |
| Net Income (ttm) | -9.33M |
| Shares Out | 27.55M |
| EPS (ttm) | -0.34 |
| PE Ratio | n/a |
| Forward PE | 12.76 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 22 |
| Last Price | $4.85 |
| Previous Close | $4.82 |
| Change ($) | 0.03 |
| Change (%) | 0.62% |
| Day's Open | 4.86 |
| Day's Range | 4.75 - 5.04 |
| Day's Volume | 154,086 |
| 52-Week Range | 4.56 - 10.98 |
Fireside Chat Being Held on Tuesday, May 4th @ 10am Eastern Time Fireside Chat Being Held on Tuesday, May 4th @ 10am Eastern Time
Bloomberg reported this morning that the world's wealthiest countries are vaccinating 25 times faster than the poorest. As of April 8, 40% of the shots administered have gone to people in 27 nations tha...
Death, Taxes, and Covid shots. The future stretching out in front of us has maybe only these three certainties.
Advancing Dyadic ' s proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial To validate C1 produced proteins are safe in humans and accelerate C1 adoption and ...
While the pandemic feels “almost over” on many levels, experts believe the fundamental driver – a rapidly mutating coronavirus pathogen with uniquely formidable qualities – is likely, and unfortunately,...
JUPITER, Fla., March 29, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, ...
JUPITER, Fla., March 23, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, ...
Dyadic International is surging today after it announced a Covid vaccine partnership with Medytox, but that isn't the only bullish news for this small cap biotech stock. The post DYAI Stock: Why Covid-1...
Odonate Therapeutics, Inc. (NASDAQ: ODT), Dyadic International, Inc. (NASDAQ: DYAI) and Marker Therapeutics, Inc. (NASDAQ: MRKR) are among the early biotech movers in Monday's session. Odonate to Shut S...
Dyadic International Inc's (NASDAQ: DYAI) initial C1 produced SARS-CoV-2-S-RBD vaccine candidate, DYAI-100, moves towards the first human Phase 1 clinical trial to assess the safety and preliminary effi...
JUPITER, FL / ACCESSWIRE / March 16, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applyin...
Results demonstrate that Dyadic's C1 platform produced record levels of safe and effective vaccines in animal trials and further positions C1 products for potential human clinical trials Results demonst...
JUPITER, FL / ACCESSWIRE / January 11, 2021 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expres...
Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q2 2020 Results - Earnings Call Transcript
This small-cap stock is developing a technology that could revolutionize biotech.
Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q1 2020 Results - Earnings Call Transcript
Dyadic International: The Pandemic Changes Everything
Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q4 2019 Results - Earnings Call Transcript
Dyadic International, Inc. (NASDAQ: DYAI) shares are trading higher on Thursday, after the company announced its platform is to be used by the Israeli Research Institution to develop a treatment for the...
Dyadic International: Disrupting Biopharma Delivery And Costs
Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q3 2019 Results - Earnings Call Transcript
Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q2 2019 Results - Earnings Call Transcript
Company’s lead product promises to greatly speed development and reduce costs of producing biologic drugs, which is currently being tested by major collaborators and at least two big pharma players.
About DYAI
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.... [Read more...]
| Industry Biotechnology | IPO Date Nov 5, 2004 |
| Stock Exchange NASDAQ | Ticker Symbol DYAI |
Financial Performance
In 2020, DYAI's revenue was $1.60 million, a decrease of -4.71% compared to the previous year's $1.68 million. Losses were -$9.33 million, 12.2% more than in 2019.
Analyst Forecasts
According to one analyst, the rating for DYAI stock is "Strong Buy" and the 12-month stock price forecast is 11.00.